The role of lysophosphatidic acid metabolism in castration-resistant prostate cancer progression

1

Prostate cancer is a leading cause of cancer-related mortality in men, with most patients developing castration-resistant prostate cancer (CRPC) after initial treatment.
2

Lysophosphatidic acid (LPA) is implicated in the progression of CRPC, promoting tumor proliferation, survival, invasion, and therapy resistance.
3

LPA engages specific receptors to activate signaling pathways that sustain prostate cancer cell growth despite androgen deprivation.
4

Dysregulation of LPA metabolism and signaling contributes to prostate cancer development and metastasis.
5

Targeting the LPA signaling pathway presents potential therapeutic strategies for managing castration-resistant prostate cancer.

1